COVID-19 et maladies cardiovasculaires.

Betacoronavirus/pathogenicity; Cardiovascular Diseases/complications; Comorbidity; Coronavirus Infections/complications; Humans; Myocardium/pathology; Pandemics; Pneumonia, Viral/complications; Prognosis; Cardiovascular disease; Myocardial injury; 2019; COVID

Abstract :

[en] COVID-2019 disease mainly affects the respiratory tract and can progress in severe cases to pneumonia, acute respiratory distress syndrome and multi-organ failure. Patients with prior cardiovascular disease are at higher risk of developing an infection and progressing to a severe form of the disease. Also, due to the growing number of infected cases, it is clear that, in addition to the typical respiratory symptoms caused by the infection, some patients suffer from cardiovascular damage. This condition can, in fact, cause significant myocardial damage, which worsens the disease and affects the prognosis. Based on the results of currently published research, it seems important to discuss the manifestations and characteristics of myocardial damage induced by COVID-19 and its impact on patient prognosis.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

HAECK, Gaëlle ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de cardiologie

ANCION, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Insuffisance cardiaque - Transplantation

MARECHAL, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Cardiologie multidisciplinaire et prévention

Oury, Cécile ; Université de Liège - ULiège > Cardiovascular Sciences-Cardiology

Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation

Language :

French

Title :

COVID-19 et maladies cardiovasculaires.

Alternative titles :

[en] COVID-19 and cardiovascular diseases

Publication date :

2020

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

226-232

Peer reviewed :

Peer reviewed

Available on ORBi :

since 08 July 2020

Statistics

Number of views

1560 (14 by ULiège)

Number of downloads

1105 (12 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Li, B, Yang, J, Zhao, F, Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China (2020) Clin Res Cardiol, , doi.org
Davenne, E, Giot, JB, Huynen, P., Coronavirus et COVID-19: le point sur une pandémie galopante Rev Med Liege, 75, pp. 218-225
Wu, Z, McGooganJM.- Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention (2020) JAMA
Wu, C, Chen, X, Cai, Y, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China (2020) JAMA Intern Med
Zheng, Y-Y, Ma, Y-T, Zhang, J-Y, COVID-19 and the cardiovascular system (2020) Nat Rev Cardiol, , doi.org
Huang, C., Wang, Y, Li, X, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China (2020) Lancet, 395, pp. 497-506
Kuster, GM, Pfister, O, Burkard, T, SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? (2020) Eur Heart J
Ferrario, CM, Jessup, J, Chappell, MC, Effect of angiotensin- converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 (2005) Circulation, 111, pp. 2605-2610
Deshotels, MR, Xia, H, Sriramula, S, Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptordependent mechanism (2014) Hypertension, 64, pp. 1368-1375
Dzau, VJ, Re, R., Tissue angiotensin system in cardiovascular medicine. A paradigm shift ? (1994) Circulation, 89, pp. 493-498
Crackower, MA, Sarao, R, Oudit, GY, Angiotensinconverting enzyme 2 is an essential regulator of heart function (2002) Nature, 417, pp. 822-828
Patel, VB, Parajuli, N, Oudit, GY., Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications (2014) Clin Sci, 126, pp. 471-482
Brosnihan, KB, Neves, LA, Chappell, MC., Does the angiotensin- converting enzyme (ACE)/ACE2 balance contribute to the fate of angiotensin peptides in programmed hypertension? (2005) Hypertension, 46, pp. 1097-1099
Chamsi-Pasha, MA, Shao, Z, Tang, WH., Angiotensin-converting enzyme 2 as a therapeutic target for heart failure (2014) Curr Heart Fail Rep, 11, pp. 58-63
Turner, AJ, Hiscox, JA, Hooper, NM., ACE2: from vasopeptidase to SARS virus receptor (2004) Trends Pharmacol Sci, 25, pp. 291-294
Hofmann, H, Geier, M, Marzi, A, Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor (2004) Biochem Biophys Res Commun, 319, pp. 1216-1221
Chen, D, Li, X, Song, Q, Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19) (2020) MedRxiv, , doi.org 02.27.20028530
Kuba, K, Imai, Y, Rao, S, A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury (2005) Nat Med, 11, pp. 875-879
ACE2, IEC/ARAII et infections à COVID-19 par la Société Française de Pharmacologie et de Thérapeutique (2020) Thérapie, 39, pp. 1-12
Zhang, H, Penninger, JM, Li, Y, Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target (2020) Intensive Care Med
Patel, AB, Verma, A., COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? (2020) JAMA
Ocaranza, MP, Godoy, I, Jalil, JE, Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat (2006) Hypertension, 48, pp. 572-578
Furuhashi, M, Moniwa, N, Mita, T, Urinary angiotensin- converting enzyme 2 in hypertensive patients may be increased by Olmesartan, an angiotensin II receptor blocker (2014) Am J Hypertens, 28, pp. 15-21
Bai, S, Huang, ZG, Chen, L, Effects of felodipine combined with puerarin on ACE2-Ang (1-7)-Mas axis in renovascular hypertensive rat (2013) Regul Pept, 184, pp. 54-61
Jessup, JA, Brosnihan, KB, Gallagher, PE, Differential effect of low dose thiazides on the Renin Angiotensin system in genetically hypertensive and normotensive rats (2008) J Am Soc Hypertens, 2, pp. 106-115
Keidar, S, Gamliel-Lazarovich, A, Kaplan, M, Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients (2005) Circ Res, 97, pp. 946-953
Wang, D, Hu, B, Hu, C, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China JAMA
Chan, JF, Yuan, S, Kok, KH, A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster (2020) Lancet, 395, pp. 514-523
Driggin, E, Madhavan, M V, Bikdeli, B, Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic J Am Coll Cardiol, , 2020 jacc.2020.03.03
Wei, ZY, Qian, HY., Myocardial injury in patients with COVID-19 pneumonia (2020) Zhonghua Xin Xue Guan Bing Za Zhi, 48, p. E006
Lippi, G, Lavie, CJ, Sanchis-Gomar, F., Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis (2020) Prog Cardiovasc Dis, , pii S0033062020300554
Vaduganathan, M, Vardeny, O, Michel, T, Renin-Angiotensin- Aldosterone System Inhibitors in Patients with Covid-19 (2020) N Engl J Med
Zheng, YY, Ma, YT, Zhang, JY, COVID-19 and the cardiovascular system (2020) Nat Rev Cardiol, , et
Oudit, GY, Kassiri, Z, Jiang, C, SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS (2009) Eur J Clin Invest, 39, pp. 618-625
Wong, CK, Lam, CW, Wu, AK, Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome (2004) Clin Exp Immunol, 136, pp. 95-103
Lancellotti, P, Moonen, M, Galderisi, M., Chimeric Antigen Receptor T-Cells and Cardiovascular Toxicity: Cause for Concern? (2019) J Am Coll Cardiol, 74, pp. 3109-3111
Wang, M, Cao, R, Zhang, L, Le remdesivir et la chloroquine inhibent efficacement in vitro le nouveau coronavirus récemment apparu (2019-nCoV) (2020) Cell Res, 30, pp. 269-271
Gautret, P, Lagier, JC, Parola, P, Hydroxychloroquine et azithromycine comme traitement de COVID-19: résultats d'un essai clinique non randomisé en ouvert. Agents antimicrobiens (2020) Int J, p. 105949
Chatre, C, Roubille, F, Vernhet, H, Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature (2018) Drug Saf, 41, pp. 919-931
Wu, Q, Zhou, L, Sun, X, Altered lipid metabolism in recovered SARS patients twelve years after infection (2017) Sci Rep, 7, p. 9110